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MaOBJECTIVES This study sought to determine mortality rates among cardiogenic shock (CGS) patients undergoing
percutaneous coronary intervention (PCI) for acute coronary syndrome in the contemporary treatment era and to
determine predictors of mortality.
BACKGROUND It is unclear whether recent advances in pharmacological and interventional strategies have resulted in
further improvements in short- and long-term mortality and which factors are associated with adverse outcomes in
patients presenting with CGS and undergoing PCI in the setting of acute coronary syndrome.
METHODS This study analyzed prospectively collected data for patients undergoing PCI in the setting of CGS as
recorded in the BCIS (British Cardiovascular Intervention Society) PCI database.
RESULTS In England and Wales, 6,489 patients underwent PCI for acute coronary syndrome in the setting of CGS. The
mortality rates at 30 days, 90 days, and 1 year were 37.3%, 40.0%, and 44.3%, respectively. On multiple logistic
regression analysis, age (for each 10-year increment of age: odds ratio [OR]: 1.59, 95% conﬁdence interval [CI]: 1.51 to
1.68; p < 0.0001), diabetes mellitus (OR: 1.47, 95% CI: 1.28 to 1.70; p < 0.0001), history of renal disease (OR:
2.03, 95% CI: 1.63 to 2.53; p < 0.0001), need for artiﬁcial mechanical ventilation (OR: 2.56, 95% CI: 2.23 to 2.94;
p < 0.0001), intra-aortic balloon pump use (OR: 1.57, 95% CI: 1.40 to 1.76; p < 0.0001), and need for left main stem PCI
(OR: 1.90, 95% CI: 1.62 to 2.23; p < 0.0001) were associated with higher mortality at 1 year.
CONCLUSIONS In this large U.K. cohort of patients undergoing PCI in the context of CGS, mortality remains high
in spite of the use of contemporary PCI strategies. The highest mortality occurs early, and this time period may be a
particular target of therapeutic intervention. (J Am Coll Cardiol Intv 2014;7:1374–85) © 2014 by the American College of
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1375AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome
AMI = acute myocardial
infarction
CGS = cardiogenic shock
CI = conﬁdence interval
IABP = intra-aortic balloon
pump
MV = multiple variable
MVD = multivessel disease
OR = odds ratio
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
TIMI = Thrombolysis In
ardial InfarctionA dvances in the management of acute myocar-dial infarction (AMI), such as the introduc-tion of early revascularization with primary
percutaneous coronary intervention and use of
potent adjunctive therapies have resulted in reduc-
tion in the reported overall mortality of AMI (from
18% in 1998 to 10% in 2009) (1–4). Cardiogenic shock
(CGS) remains a major cause of mortality, however,
with death in patients deﬁned as suffering from CGS
reported to have remained high. Mortality rates
recorded in the 1990s were reported to be >50%
(1–4). CGS describes the pathophysiological state
in which reduced cardiac output and resultant tissue
hypoxia occur in the presence of adequate intravas-
cular volume. Hemodynamically, the deﬁnition of
CGS is open to some debate but can be deﬁned as a
fall in systolic blood pressure below 90 mm Hg
sustained for at least 30 min in the absence of hypo-
volemia, with a cardiac index below 1.8 l/min/m2
without support or 2.0 to 2.2 l/min/m2 with support,
and in the presence of a raised pulmonary capillary
wedge pressure (>15 mm Hg) (2,5). The aims of this
study were to determine the contemporary 30-day,
90-day, and 1-year mortality outcomes and to deter-
mine predictors of 1-year mortality in patients
undergoing percutaneous coronary intervention
(PCI) in the setting of acute coronary syndrome
(ACS) and CGS.
METHODS
STUDY DESIGN. This was an observational cohort
study. The British Cardiovascular Intervention Soci-
ety oversees the collection of data comprising all
PCI performed in the United Kingdom. There are
117 centers from the 4 U.K. countries (Scotland 8,
England 101, Northern Ireland 4, Wales 4). These data
are encrypted and sent from each PCI center to
servers now hosted by the National Institute for
Clinical Outcomes Research based at University Col-
lege London, as previously described (6). In sum-
mary, the BCIS (British Cardiovascular Intervention
Society) registry dataset includes a total of 113 vari-
ables that describe baseline characteristics, clinical
presentation, procedural details, and procedural
complications. These data are prospectively collected
at the end of each procedure under the responsibility
of the performing interventional cardiologist. Peri-
and post-procedural complications, clinical data, and
discharge medications are subsequently updated on
discharge. Reliable mortality tracking is possible for
patients from England and Wales using their National
Health Service number (a unique identiﬁer). Tracking
is performed by the Medical Research InformationService using data from the Ofﬁce of National
Statistics for patients in England and Wales.
It was the robust nature of the follow-up
outcomes with the England and Wales data
that led us to use these tracked data as the
basis of our observational report. An accepted
deﬁnition of CGS is “persistent hypotension
(systolic blood pressure <80 to 90 mm Hg or
mean arterial pressure 30 mm Hg lower than
baseline) with severe reduction in cardiac
index (<1.8 l/min/m2 without support or <2.0
to 2.2 l/min/m2 with support) and adequate or
elevated ﬁlling pressure (e.g., left ventricular
end-diastolic pressure >18 mm Hg or right
ventricular end-diastolic pressure >10 to
15 mm Hg) (2,5).” Because such hemodynamic
measurements are rarely available in the
clinical setting of primary and emergency
PCI, in the BCIS registry, CGS was deﬁned on
clinical criteria when a patient fulﬁlled the following
minimal conditions: persistent hypotension with
clinical evidence of hypoperfusion (cool, clammy,
oliguric, altered mental status) with dependence on
inotropes or mechanical left ventricular support to
correct this situation. Such strict clinical criteria
allowed us to ensure patients entered into this reg-
istry were highly likely (in the clinical context of
needing PCI for ACS), to be suffering CGS. Key deﬁ-
nitions for variables used in the BCIS dataset are
shown in the Online Appendix.
STATISTICAL ANALYSIS. Data are presented as per-
centages for categorical variables and as means  SD
for continuous variables. Logistic regression was
applied to detect the association of baseline charac-
teristics, angiographic, and procedural characteristics
with mortality. The 30-day, 90-day, and 1-year
mortality rates were calculated. Multiple logistic
regressions were applied to evaluate predictors of
1-year mortality. In multiple logistic regression anal-
ysis, analysis was performed under the assumption
that missing values were missing completely at
random. We also performed an analysis assuming
that the missing values were not missing at random
using multiple imputations (7) to determine whether
it makes a difference in the results. Both results are
shown in tables whereas the results from not missing
at random analysis are reported in the abstract and
main text. Distribution of time to event was esti-
mated by using Kaplan-Meier method. All tests in the
analyses were 2-sided tests. A p value <0.05 was
considered statistically signiﬁcant. All statistical
analyses were performed using SAS (version 9.3,
SAS Inc., Cary, North Carolina).
Myoc
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The study ﬂowchart is displayed in Figure 1. An initial
dataset consisting of 501,117 PCI procedures from all
centers from the BCIS database in the United
Kingdom were available for consideration. Of these,
6,489 patients were used as the patient observational
group because they were recorded as having under-
gone PCI for ACS in the setting of CGS in England and
Wales and had complete 1-year mortality tracking.
Figure 2 shows the incidence of shock over time. The
baseline, angiographic, and procedural characteristics
for all patients in this study cohort (N ¼ 6,489), those
who died (group 1: n ¼ 2,872), and those who were
alive at 1 year (group 2: n ¼ 3,617) are displayed in
Tables 1 and 2.
BASELINE CHARACTERISTICS. The baseline charac-
teristics are displayed in Table 1. Patients in group
1 were older than those in group 2 (70.5 years vs.
64.4 years, p < 0.0001). Furthermore, in group 1, the
following baseline parameters were more common
than in group 2: female sex (30.5% vs. 28%, p ¼ 0.03),
history of hypertension (53% vs. 46.7%, p < 0.0001),FIGURE 1 Study Flowchart
The ﬂowchart describes the population that underwent percutaneous co
2005 and 2011. ACS ¼ acute coronary syndrome; NICOR ¼ National Insdiabetes (25.5% vs. 16.5%, p < 0.0001), previous
myocardial infarction (29.9% vs. 24.3%, p < 0.0001),
chronic renal disease (12.9% vs. 4.8%, p < 0.0001),
acute stent thrombosis (2.0% vs. 1.2%, p ¼ 0.0105),
and primary PCI procedure (61.7% vs. 56.6%, p <
0.0001). The rate of CGS in the entire group of
patients with unstable angina, non–ST-segment
elevation myocardial infarction (STEMI), convales-
cent STEMI, and STEMI (includes primary PCI, rescue
PCI, facilitated PCI, and reinfarction) was 2.6%.
ANGIOGRAPHIC AND PROCEDURAL CHARACTERISTICS.
The angiographic and procedural characteristics are
shown in Table 2. More patients in group 1 had TIMI
(Thrombolysis In Myocardial Infarction) ﬂow grade
0 (for deﬁnition see the Online Appendix) at the start
of the PCI procedure than did those in group 2
(69.4% vs. 66.1%, p ¼ 0.0166). In group 1, compared
with group 2, there was a signiﬁcantly higher number
of lesions treated (1.7  1.0 vs. 1.5  0.9, p < 0.0001),
left main PCI (19.9% vs. 9.7%, p < 0.0001), femoral
procedures (85.0% vs. 77.8%, p < 0.0001), need for
artiﬁcial ventilation (37.7% vs. 20.9%, p < 0.0001),
perceived need for intra-aortic balloon pump (IABP)ronary intervention (PCI) in the setting of cardiogenic shock between
titute for Clinical Outcomes Research.
FIGURE 2 Incidence of CGS Over Time
The graphs describe the percentage of cardiogenic shock (CGS) cases over time (2005 to
2010) in the setting of acute coronary syndrome (ACS).
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1377(56.6% vs. 42%, p < 0.0001), TIMI ﬂow grade 0 post-
PCI (13.3% vs. 5.4%, p < 0.0001), incidence of rein-
farction (0.8% vs. 0.3%, p ¼ 0.0072), renal failure/
dialysis (2.3% vs. 0.9%, p < 0.0001), cardiac tampo-
nade (0.7% vs. 0.1%, p ¼ 0.0018), heart block
requiring pacing (5.5% vs. 2.5%, p < 0.0001), direct
current cardioversion (6.3% vs. 2.9%, p < 0.0001),
and no ﬂow/slow ﬂow during PCI (8.7% vs. 4.1%,
p < 0.0001). Abciximab was used less frequently in
group 1 than in group 2 (47.3% vs. 52.1, p < 0.0002).
Multivessel PCI was performed in 28.5% of patients.
MORTALITY FOLLOWING CGS. The overall 30-day,
90-day, and 1-year mortality rates following PCI for
CGS were 37.3%, 40.0%, and 44.3%, respectively.
Analysis of the BCIS annual audit reports indicates
that in patients without CGS, the overall 30-day,
90-day, and 1-year mortality rates following PCI in
the setting of ACS were 2.0%, 2.81%, and 5.14%,
respectively. Mortality rate according to the year of
presentation is shown in Figure 3. The Kaplan-Meier
curve for mortality is displayed in Figure 4. For
patients with CGS, the 1-year mortality for patients
who were known to be alive at 30 days was 11.1%. The
1-year mortality for ACS patients without CGS but
with similar age-sex distribution as those of shock
patients who were alive at 30 days was 5.7%.
PREDICTORS OF 30-DAY MORTALITY. Multiple
regression analysis was initially performed excluding
procedure-related variables (artiﬁcial ventilation,
IABP use, and radial procedure) and is displayed in
Table 3. Age (for each 10-year increment: odds ratio
[OR]: 1.35, 95% conﬁdence interval [CI]: 1.29 to 1.41;
p < 0.0001), history of renal disease (OR: 1.63, 95% CI:
1.34 to 1.98; p < 0.0001), diabetes mellitus (OR: 1.34,
95% CI: 1.17 to 1.54; p < 0.0001), and left main disease
(OR: 1.49, 95% CI: 1.28 to 1.75; p < 0.0001) were
signiﬁcant in predicting 30-day mortality. TIMI ﬂow
grade 3 pre-PCI (OR: 0.74, 95% CI: 0.62 to 0.88;
p ¼ 0.001), and TIMI ﬂow grade 3 post-PCI (OR: 0.44,
95% CI: 0.38 to 0.50; p < 0.0001) were associated with
reduced 30-day mortality.
When procedure-related variables were included in
the multiple variable (MV) logistic regression, the
following parameters were associated with a greater
likelihood of dying at 30 days: age (for each 10-year
increment: OR: 1.45, 95% CI: 1.38 to 1.52; p < 0.0001);
history of renal disease (OR: 1.55, 95% CI: 1.25 to 1.91;
p< 0.0001); diabetes mellitus (OR: 1.26, 95% CI: 1.10 to
1.45; p¼0.001); need for artiﬁcial ventilation (OR: 2.59,
95% CI: 2.28 to 2.95; p < 0.0001); IABP use (OR: 1.56,
95% CI: 1.39 to 1.76; p< 0.0001); and left main PCI (OR:
1.56, 95% CI: 1.34 to 1.83; p< 0.0001). TIMI ﬂow grade 3
pre-PCI (OR: 0.76, 95% CI: 0.62 to 0.95; p ¼ 0.0145),TIMI ﬂow grade 3 post-PCI (OR: 0.41, 95% CI: 0.35 to
0.47; p< 0.0001), and radial procedures (OR: 0.71, 95%
CI: 0.62 to 0.81; p < 0.0001) were associated with
reduced 30-day mortality (Table 4).
TABLE 1 Baseline Characteristics (Stratiﬁed by 1-Year Mortality)
Total
(N ¼ 6,489)
Died, Group 1
(n ¼ 2,872)
Alive, Group 2
(n ¼ 3,617) p Value
Variables
Mean age, yrs 67.1  12.6 70.5  11.9 64.4  12.5 <0.0001
Female 1,879/6,454 (29.1) 870/2,855 (30.5) 1,009/3,599 (28.0) 0.0323
Hypertension 2,903/5,877 (49.4) 1,348/2,544 (53.0) 1,555/3,333 (46.7) <0.0001
Diabetes mellitus 1,218/5,959 (20.4) 662/2,593 (25.5) 556/3,366 (16.5%) <0.0001
Hypercholesterolemia 2,751/5,877 (46.8) 1,216/2,544 (47.8) 1,535/3,333 (46.1) 0.1842
Previous myocardial infarction 1,493/5,596 (26.7) 722/2,419 (29.9) 771/3,177 (24.3) <0.0001
Previous PCI 843/6,111 (13.8) 392/2,674 (14.7) 451/3,437 (13.1) 0.0839
Previous CABG 312/6,150 (5.1) 142/2,700 (5.3) 170/3,450 (4.9) 0.5550
Family history of CAD 1,824/4,730 (38.6) 703/1,941 (36.2) 1,121/2,789 (40.2) 0.0057
Smoking, ever smoker 3,485/5,138 (67.8) 1,399/2,119 (66.0) 2,086/3,019 (69.1) 0.0203
History of renal disease 472/5,686 (8.3) 315/2,437 (12.9) 157/3,249 (4.8) <0.0001
Indication for intervention
Acute/subacute stent thrombosis 100/6,489 (1.5) 57/2,872 (2.0) 43/3,617 (1.2) 0.0105
UA/NSTEMI/convalescent STEMI 1,642/6,489 (25.3) 670/2,872 (23.3) 972/3,617 (26.9) 0.0011
Primary PCI 3,819/6,489 (59.0) 1,771/2,872 (61.7) 2,048/3,617 (56.6) <0.0001
Facilitated PCI 76/6,489 (1.2) 16/2,872 (0.6) 60/3,617 (1.7) <0.0001
Rescue PCI 596/6,489 (9.2) 249/2,872 (8.7) 347/3,617 (9.6) 0.2009
Reinfarction rescue PCI 116/6,489 (1.8) 46/2,872 (1.6) 70/3,617 (1.9) 0.3144
PCI for reinfarction 140/6,489 (2.2) 63/2,872 (2.2) 77/3,617 (2.1) 0.8582
Admission route
Direct to cardiac center 3,374/6,043 (55.8) 1,478/2,672 (55.3) 1,896/3,371 (56.2) 0.4695
Interhospital transfer 2,020/6,043 (33.4) 865/2,672 (32.4) 1,155/3,371 (34.3) 0.1226
Already in cardiac center 630/6,043 (10.4) 324/2,672 (12.1) 306/3,371 (9.1) 0.0001
Recent lysis 931/5,917 (15.7) 348/2,619 (13.3) 583/3,298 (17.7) <0.0001
Values are mean  SD or n/N (%).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction; UA ¼ unstable angina.
Kunadian et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 2 , 2 0 1 4
Cardiogenic Shock in the Contemporary Era D E C E M B E R 2 0 1 4 : 1 3 7 4 – 8 5
1378PREDICTORS OF 1-YEAR MORTALITY. Multiple
regression analysis was initially performed excluding
procedure-related variables (artiﬁcial ventilation,
IABP use, and radial procedure) and is displayed in
Table 5. Age (for each 10-year increment: OR: 1.48,
95% CI: 1.41 to 1.55; p < 0.0001), diabetes mellitus
(OR: 1.54, 95% CI: 1.34 to 1.77; p < 0.0001), history
of renal disease (OR: 2.10, 95% CI: 1.72 to 2.58;
p < 0.0001), and left main disease (OR: 1.71, 95% CI:
1.46 to 2.01; p < 0.0001) were signiﬁcant in predicting
1-year mortality. TIMI ﬂow grade 3 post-PCI (OR: 0.47,
95% CI: 0.41 to 0.55; p < 0.0001) was associated with
reduced 1-year mortality.
Using MV logistic regression including procedure-
related variables such as IABP use, need for artiﬁcial
ventilation, left main PCI, and radial procedure,
the following parameters were associated with a
greater likelihood of dying at 1 year: age (for each
10-year increment: OR: 1.59, 95% CI: 1.51 to 1.68;
p < 0.0001); diabetes mellitus (OR: 1.47, 95% CI: 1.28
to 1.70; p < 0.0001); history of renal disease (OR:
2.03, 95% CI: 1.63 to 2.53; p < 0.0001); need for arti-
ﬁcial ventilation (OR: 2.56, 95% CI: 2.23 to 2.94;p < 0.0001); IABP use (OR: 1.57, 95% CI: 1.40 to 1.76;
p < 0.0001); and left main PCI (OR: 1.90, 95% CI: 1.62
to 2.23; p < 0.0001) remained associated with
increased mortality at 1 year. TIMI ﬂow grade 3
post-PCI (OR: 0.44, 95% CI: 0.37 to 0.51; p < 0.0001)
and radial procedures (OR: 0.79, 95% CI: 0.69 to 0.90;
p ¼ 0.0008) were associated with reduced 1-year
mortality (Table 6).
DISCUSSION
This study used an established large national data-
base of consecutive patients presenting with CGS
undergoing PCI in the contemporary era and showed
that mortality remains high in this group. Despite an
apparent modest fall compared with historical data,
an annual mortality of 44% in these patients suggests
that there remains substantial room for improvement
in the management of such patients. This study has
also demonstrated that age, diabetes mellitus, history
of renal disease, need for artiﬁcial ventilation,
perceived need for IABP, and left main disease/PCI
were independently associated with increased
TABLE 2 Procedural Characteristics (Stratiﬁed by 1-Year Mortality)
Total
(N ¼ 6,489)
Died, Group 1
(n ¼ 2,872)
Alive, Group 2
(n ¼ 3,617) p Value
Pre-PCI LMS stenosis, 75%–100% 735/4,945 (14.9) 453/2,207 (20.5) 282/2,738 (10.3) <0.0001
TIMI ﬂow grade pre-PCI
0 3,164/4,683 (67.6) 1,478/2,131 (69.4) 1,686/2,552 (66.1) 0.0166
1 477/4,683 (10.2) 202/2,131 (9.5) 275/2,552 (10.8) 0.1443
2 490/4,683 (10.5) 222/2,131 (10.4) 268/2,552 (10.5) 0.9256
3 552/4,683 (11.8) 229/2,131 (10.8) 323/2,552 (12.7) 0.0437
Lesions attempted 1.6  0.9 1.7  1.0 1.5  0.9 <0.0001
Stents per lesion 1.7  1.3 1.7  1.4 1.7  1.2 0.2235
Drug-eluting stents 0.8  1.2 0.7  1.2 0.9  1.2 <0.0001
Radial procedure 1,428/6,340 (22.5) 526/2,812 (18.7) 902/3,528 (25.6) <0.0001
Femoral procedure 5,133/6,340 (81.0) 2,389/2,812 (85.0) 2,744/3,528 (77.8) <0.0001
Left main PCI 911/6,413 (14.2) 565/2,839 (19.9) 346/3,574 (9.7) <0.0001
Graft vessel PCI 173/6,413 (2.7) 77/2,839 (2.7) 96/3,574 (2.7) 0.9488
Use of glycoprotein IIb/IIIa inhibitors
None 2,482/6,196 (40.1) 1,172/2,736 (42.8) 1,310/3,460 (37.9) <0.0001
Abciximab 3,099/6,196 (50.0) 1,295/2,736 (47.3) 1,804/3,460 (52.1) 0.0002
Eptiﬁbatide 272/6,196 (4.4) 115/2,736 (4.2) 157/3,460 (4.5) 0.5256
Tiroﬁban 283/6,196 (4.6) 133/2,736 (4.9) 150/3,460 (4.3) 0.3225
Ventilated patients 1,655/5,828 (28.4) 981/2,602 (37.7) 674/3,226 (20.9) <0.0001
IABP use 2,971/6,120 (48.6) 1,547/2,733 (56.6) 1,424/3,387 (42.0) <0.0001
Lesions successful 1.4  0.9 1.4  1.0 1.4  0.8 0.8554
TIMI ﬂow grade post-PCI
0 449/5,006 (9.0) 299/2,241 (13.3) 150/2,765 (5.4) <0.0001
1 160/5,006 (3.2) 123/2,241 (5.5) 37/2,765 (1.3) <0.0001
2 544/5,006 (10.9) 325/2,241 (14.5) 219/2,765 (7.9) <0.0001
3 3,853/5,006 (77.0) 1,494/2,241 (66.7) 2,359/2,765 (85.3) <0.0001
PCI hospital outcome
Q-wave MI 37/6,184 (0.6) 20/2,753 (0.7) 17/3,431 (0.5) 0.2446
Non–Q-wave MI 14/6,184 (0.2) 4/2,753 (0.2) 10/3,431 (0.3) 0.2391
Emergency CABG 17/6,184 (0.3) 10/2,753 (0.4) 7/3,431 (0.2) 0.2393
Arterial complication 61/6,184 (1.0) 27/2,753 (1.0) 34/3,431 (1.0) 0.9678
CVA emboli 20/6,184 (0.3) 12/2,753 (0.4) 8/3,431 (0.2) 0.1690
CVA bleed 19/6,184 (0.3) 9/2,753 (0.3) 10/3,431 (0.3) 0.8014
TIA/RIND 7/6,184 (0.1) 4/2,753 (0.2) 3/3,431 (0.1) 0.5032
Reintervention PCI 82/6,184 (1.3) 36/753 (1.3) 46/3,431 (1.3) 0.9102
Repeat catheterization, no PCI 22/6,184 (0.4) 7/2,753 (0.3) 15/3,431 (0.4) 0.2357
Reinfarction 30/6,184 (0.5) 21/2,753 (0.8) 9/3,431 (0.3) 0.0072
Blood transfusion 148/6,184 (2.4) 64/2,753 (2.3) 84/3,431 (2.5) 0.7528
Renal failure/dialysis 96/6,184 (1.6) 64/2,753 (2.3) 32/3,431 (0.9) <0.0001
GI bleed 75/6,184 (1.2) 36/2,753 (1.3) 39/3,431 (1.1) 0.5395
Tamponade 22/6,184 (0.4) 18/2,753 (0.7) 4/3,431 (0.1) 0.0018
Platelet transfusion 28/6,184 (0.5) 12/2,753 (0.4) 16/3,431 (0.5) 0.8599
Procedural complications
Side branch occlusion 54/5,868 (0.9) 29/2,624 (1.1) 25/3,244 (0.8) 0.1844
Coronary dissection 137/5,868 (2.3) 82/2,624 (3.1) 55/3,244 (1.7) 0.0004
Coronary perforation 25/5,868 (0.4) 16/2,624 (0.6) 9/3,244 (0.3) 0.0582
Heart block requiring pacing 226/5,868 (3.9) 144/2,624 (5.5) 82/3,244 (2.5) <0.0001
DC cardio version 259/5,868 (4.4) 165/2,624 (6.3) 94/3,244 (2.9) <0.0001
No ﬂow/slow ﬂow 359/5,868 (6.1) 227/2,624 (8.7) 132/3,244 (4.1) <0.0001
Values are mean  SD or n/N (%).
CVA ¼ cerebrovascular event; DC ¼ direct current; GI ¼ gastrointestinal; IABP ¼ intra-aortic balloon pump; LMS ¼ left main stem; MI ¼ myocardial infarction;
RIND ¼ reversible ischemic neurologic deﬁcit; TIA ¼ transient ischemic attack; TIMI ¼ Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
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FIGURE 3 Mortality in CGS
The graphs describe the mortality in CGS cases over time (2005 to 2010) in the setting of
ACS. Abbreviations as in Figure 2.
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1380mortality rates at 1 year following PCI in the setting of
CGS. Our data have also illustrated the relatively low
subsequent mortality rate for those patients with CGS
who survive the ﬁrst 30 days. This suggests that
endeavors to change the natural trajectory of this
condition should focus on interventions that can be
provided in the acute phase.
This study offers insights over the existing litera-
ture in 3 ways. The treatment of patients with acute
coronary syndromes continues to evolve, and this
study is important in reﬂecting contemporary prac-
tice. With 6,489 patients, it is the largest cohort of
consecutive unselected patients studied in the setting
of CGS. Finally our data describes mortality rates not
only for the short-term (30 days and 90 days) but also
in the longer term (1 year) following PCI in the
setting of CGS. This comparison of 30-day and 1-year
mortality data demonstrated an interesting observa-
tion on the plateau-like nature of the mortality curve
over time.
These results highlight the persistently poor
outcome for PCI in CGS in the contemporary period.
Despite early mortality appearing to have improved
when compared with historical studies, concomitant
perhaps with a broader use of PCI and recommended
adjunctive medications in the acute stage, the 1-year
mortality remains high and appears to be inﬂuenced
less than may have been expected by contemporary
adjunctive treatments (8). The management of STEMI
in general has evolved rapidly over the last 5 to
10 years so that the majority of patients in the United
Kingdom now have access to primary PCI. However,
despite the use of the same such contemporary
management strategies in CGS patients over the same
period, the current study shows that mortality
remains disappointingly high in the short term
(30-day mortality: 37.3%) with further albeit less later
attrition (1-year mortality: 44.3%). Our mortality rates
are comparable to a recent analysis of STEMI patients
with CGS where the in-hospital mortality was 39% (9).
The size of the reported cohort allows us to
describe important predictors of poor outcome in this
condition. Thus, for example, age as might have been
expected, was an independent predictor of mortality
at 1 year in our study. This is consistent with other
observational studies such as that from the GRACE
(Global Registry of Acute Coronary Events) (10) and
others demonstrating increased mortality with
advanced age in ACS. In another small study of
patients with CGS, 1 multiple predictor of in-hospital
mortality was age $75 years (hazard ratio: 1.81, 95%
CI: 1.006 to 3.27; p ¼ 0.04) (11). Optimal treatment
strategies for older patients presenting with CGS and
undergoing PCI are not known and warrant further
FIGURE 4 Kaplan-Meier Curve for Mortality
The graph shows 1-year mortality following percutaneous coronary intervention in
cardiogenic shock.
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1381study. Tailoring speciﬁc therapy toward the older
patients, who may be susceptible to bleeding from
access site is underconsidered in this and other
conditions.
Previous studies have demonstrated that diabetes
is associated with higher in-hospital and long-term
mortality in patients with MI complicated by CGS
(12). In our study, presence of diabetes on multiple
analyses was an independent predictor of 1-year
mortality, a ﬁnding that is consistent with previous
observations from the PL-ACS (Polish Registry of
Acute Coronary Syndromes) (12). However, our study
and that of PL-ACS (both studies reﬂecting contem-
porary practice) are discrepant with the SHOCK
(Should We Emergently Revascularize Occluded Cor-
onary Arteries for CGS Trial and Registry) (which was
performed in the 1990s) with the latter showing no
difference in adjusted in-hospital mortality among
diabetic CGS patients (13). The reasons for the dif-
ferences are unclear other than the contemporary
timing of the study. Our data suggests that better
treatment strategies to improve survival among dia-
betic patients in the contemporary era are required,
although some factors may be indirect in their
impact, such as the extent of disease that is deemed
not feasible/suitable for revascularization among the
diabetic cohort, which may play an important role in
the overall outcomes in such patients.
This study unsurprisingly found that need for
artiﬁcial ventilation was an independent predictor of
1-year mortality using multiple analyses. Such pa-
tients most often present following out-of-hospitalTABLE 3 Predictors of 30-Days Survival Following PPCI in the Settin
Odds R
(
Age for each 10-yr increment, yrs 1.41
Sex, female vs. male 1.04
Hypertension 1.17
Diabetes Mellitus 1.26
Previous MI 1.31
Previous PCI 0.79
Previous CABG 0.97
H/O renal disease 1.97
Smoking status, reference group: never smokers 1.00
Use of glycoprotein IIb/IIIa inhibitor 0.91
Graft vessel PCI 0.90
Left main disease, reference group: 0%–74% 1.42
Pre-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.62
Post-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.33
Multiple logistic regressions without covariates artiﬁcial ventilation, radial procedure, an
data ¼ 2,687, total events ¼ 926. *Odds ratio (95% CI) and p values after applying multip
data.
CGS ¼ cardiogenic shock; CI ¼ conﬁdence interval; MCAR ¼ missing completely at rand
intervention; other abbreviations as in Tables 1 and 2.cardiac arrest, and their risk is compounded by the
presence of other important factors, including the
degree of recoverable neurological status and meta-
bolic disturbance, which are usually not clear at the
time of PCI. Strategies to improve survival among
these ventilated patients are developing, including in
particular therapeutic hypothermia (14), but more
innovative interventions are likely to be required.
Details of the extent of use of therapeuticg of CGS
atio (95% CI)
MCAR) p Value
Odds Ratio (95% CI)*
(NMAR) p Value*
N†
Missing % Missing
(1.31–1.52) <0.0001 1.35 (1.29–1.41) <0.0001 2 0.00
(0.86–1.26) 0.6640 1.04 (0.92–1.17) 0.5178 35 0.54
(0.98–1.40) 0.0799 1.00 (0.89–1.12) 0.9807 612 9.43
(1.02–1.56) 0.0327 1.34 (1.17–1.54) <0.0001 530 8.17
(1.04–1.66) 0.0245 1.08 (0.93–1.25) 0.3009 893 13.76
(0.59–1.05) 0.1053 0.94 (0.78–1.14) 0.5417 378 5.83
(0.56–1.69) 0.9254 0.90 (0.67–1.22) 0.5081 339 5.22
(1.42–2.73) <0.0001 1.63 (1.34–1.98) <0.0001 803 12.37
(0.83–1.20) 0.9982 1.03 (0.91–1.17) 0.6205 1351 20.82
(0.76–1.09) 0.3197 0.95 (0.85–1.06) 0.3728 293 4.52
(0.45–1.82) 0.7731 0.85 (0.57–1.25) 0.4035 76 1.17
(1.10–1.82) 0.0064 1.49 (1.28–1.75) <0.0001 1,386 21.40
(0.46–0.82) 0.0009 0.74 (0.62–0.88) 0.0010 1,767 27.20
(0.27–0.40) <0.0001 0.44 (0.38–0.50) <0.0001 1,483 22.90
d IABP use in the model. Total sample size ¼ 6,489, sample entered into MV model without missing
le imputation NMAR (all 6,489 subjects were used; total events ¼ 2,422). †Case records with missing
om; MV ¼ multiple variable; NMAR ¼ not missing at random; PPCI ¼ primary percutaneous coronary
TABLE 4 Predictors of 30-Days Survival Following PPCI in the Setting of CGS (Multiple Logistic Regressions)
Odds Ratio (95% CI)
(MCAR) p Value
Odds Ratio (95% CI)*
(NMAR) p Value*
N†
Missing % Missing
Age for each 10-yr increment, yrs 1.55 (1.43–1.68) <0.0001 1.45 (1.38–1.52) <0.0001 2 0.00
Sex, female vs. male 1.07 (0.88–1.31) 0.4720 1.08 (0.95–1.22) 0.2512 35 0.54
Hypertension 1.16 (0.96–1.39) 0.1186 1.03 (0.91–1.16) 0.6320 612 9.43
Diabetes mellitus 1.22 (0.98–1.51) 0.0803 1.26 (1.10–1.45) 0.0010 530 8.17
Previous MI 1.32 (1.04–1.69) 0.0237 1.06 (0.91–1.23) 0.4638 893 13.76
Previous PCI 0.76 (0.56–1.02) 0.0678 0.95 (0.80–1.14) 0.5733 378 5.83
Previous CABG 0.86 (0.50–1.49) 0.6004 0.85 (0.63–1.15) 0.2979 339 5.22
H/O renal disease 2.00 (1.44–2.79) <0.0001 1.55 (1.25–1.91) <0.0001 803 12.37
Smoking status, reference group: never smokers 0.96 (0.80–1.17) 0.7067 1.05 (0.92–1.20) 0.4823 1351 20.82
Radial procedure 0.82 (0.67–1.01) 0.0643 0.71 (0.62–0.81) <0.0001 149 2.30
Use of glycoprotein IIb/IIIa inhibitor 0.92 (0.77–1.11) 0.3943 0.96 (0.85–1.08) 0.4504 293 4.52
Ventilated patients 3.15 (2.57–3.86) <0.0001 2.59 (2.28–2.95) <0.0001 661 10.19
IABP use 1.76 (1.47–2.11) <0.0001 1.56 (1.39–1.76) <0.0001 369 5.69
Graft vessel PCI 1.16 (0.60–2.27) 0.6599 1.01 (0.67–1.53) 0.9436 75 1.16
Left main PCI 1.73 (1.33–2.24) <0.0001 1.56 (1.34–1.83) <0.0001 75 1.16
Pre-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.61 (0.45–0.83) 0.0014 0.76 (0.62–0.95) 0.0145 1,767 27.20
Post-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.30 (0.24–0.37) <0.0001 0.41 (0.35–0.47) <0.0001 1,483 22.90
Multiple logistic regressions including covariates artiﬁcial ventilation, radial procedure, and IABP use in the model. Total sample size ¼ 6,489, sample entered into MV model without missing
data ¼ 2,783, total events ¼ 962. *Odds ratio (95% CI) and p values after applying multiple imputation NMAR (all 6,489 subjects were used; total events ¼ 2,422). †Case records with missing
data.
Abbreviations as in Tables 1 to 3.
TABLE 5
Age, yrs
Sex, fema
Hypertens
Diabetes m
Previous M
Previous P
Previous C
History of
Smoking s
Use of gly
Graft vess
Left main
Pre-PCI TI
Post-PCI T
Multiple log
data ¼ 2,68
missing dat
Abbreviat
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1382hypothermia in our study are not available from the
dataset. The question as to whether the use of ther-
apeutic hypothermia in the setting of CGS, within or
without the context of cardiac arrest, which could
lead to improved survival is so far unknown, but our
study highlights that this may be an area worthy of
further study.
Our study demonstrated that IABP use was an
independent predictor of 1-year mortality. It is likelyPredictors of 1-Year Survival Following PPCI in the Setting of CGS
Odds Ratio (95% CI)
(MCAR)
1.53 (1.42–1.64)
le vs. male 0.96 (0.80–1.16)
ion 1.04 (0.87–1.24)
ellitus 1.45 (1.18–1.79)
I 1.25 (0.99–1.58)
CI 0.88 (0.66–1.16)
ABG 0.77 (0.45–1.33)
renal disease 2.31 (1.65–3.25)
tatus, reference group: never smokers 0.99 (0.83–1.19)
coprotein IIb/IIIa inhibitor 0.96 (0.81–1.15)
el PCI 1.07 (0.54–2.13)
disease, reference group: 0%–74% 1.70 (1.33–2.18)
MI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.76 (0.58–1.00)
IMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.34 (0.28–0.42)
istic regressions without covariates artiﬁcial ventilation, radial procedure, and IABP use in th
7, total events ¼ 1,073. *Odds ratio (95% CI) and p values after applying multiple imputa
a.
ions as in Tables 1 to 3.that IABP use is simply a marker of worse clinical
state at presentation and the perception in operators’
minds that it might be of value in such patients. The
beneﬁts of IABP use have recently been questioned.
In 1 study, the use of IABP did not signiﬁcantly reduce
30-day mortality among patients with CGS compli-
cating AMI in whom an early revascularization strat-
egy was planned (15). In another study, IABP was
used only in one-quarter of patients with CGS treatedp Value
Odds Ratio (95% CI)*
(NMAR) p Value*
N†
Missing % Missing
<0.0001 1.48 (1.41–1.55) <0.0001 2 0.00
0.6809 0.96 (0.85–1.08) 0.5143 35 0.54
0.6575 0.93 (0.83–1.04) 0.2167 612 9.43
0.0005 1.54 (1.34–1.77) <0.0001 530 8.17
0.0582 1.10 (0.94–1.27) 0.2253 893 13.76
0.3568 1.06 (0.89–1.27) 0.4984 378 5.83
0.3549 0.80 (0.60–1.07) 0.1315 339 5.22
<0.0001 2.10 (1.72–2.58) <0.0001 803 12.37
0.9374 1.04 (0.92–1.18) 0.5439 1,351 20.82
0.6560 0.93 (0.83–1.04) 0.21 293 4.52
0.8451 0.88 (0.60–1.29) 0.52 76 1.17
<0.0001 1.71 (1.46–2.01) <0.0001 1,386 21.36
0.0468 0.85 (0.71–1.02) 0.0745 1,767 27.20
<0.0001 0.47 (0.41–0.55) <0.0001 1,483 22.90
e model. Total sample size ¼ 6,489, sample entered into MV model without missing
tion NMAR (all 6,489 subjects were used; total events ¼ 2,872). †Case records with
TABLE 6 Predictors of 1-Year Survival Following PPCI in the Setting of CGS (Multiple Logistic Regressions)
Odds Ratio (95% CI)
(MCAR) p Value
Odds Ratio (95% CI)*
(NMAR) p Value*
N†
Missing % Missing
Age, yrs 1.68 (1.56–1.82) <0.0001 1.59 (1.51–1.68) <0.0001 2 0.00
Sex, female vs. male 1.02 (0.85–1.24) 0.8201 0.99 (0.88–1.12) 0.9009 35 0.54%
Hypertension 1.04 (0.87–1.25) 0.6741 0.95 (0.85–1.07) 0.4295 612 9.43
Diabetes mellitus 1.40 (1.13–1.74) 0.0022 1.47 (1.28–1.70) <0.0001 530 8.17
Previous MI 1.29 (1.01–1.64) 0.0397 1.06 (0.91–1.24) 0.4372 893 13.76
Previous PCI 0.84 (0.62–1.12) 0.2240 1.09 (0.91–1.30) 0.3632 378 5.83
Previous CABG 0.75 (0.44–1.28) 0.2828 0.76 (0.56–1.03) 0.0792 339 5.22
History of renal disease 2.40 (1.70–3.40) <0.0001 2.03 (1.63–2.53) <0.0001 803 12.37
Smoking status, reference group: never smokers 0.93 (0.77–1.12) 0.4365 1.06 (0.93–1.22) 0.3617 1,351 20.82
Radial procedure 0.92 (0.75–1.12) 0.4157 0.79 (0.69–0.90) 0.0008 149 2.30
Use of glycoprotein IIb/IIIa inhibitors 0.99 (0.83–1.19) 0.9189 0.93 (0.83–1.05) 0.2546 293 4.52
Ventilated patients 3.06 (2.50–3.75) <0.0001 2.56 (2.23–2.94) <0.0001 661 10.19
IABP use 1.70 (1.43–2.03) <0.0001 1.57 (1.40–1.76) <0.0001 369 5.69
Graft vessel PCI 1.20 (0.62–2.33) 0.5810 1.11 (0.74–1.65) 0.6217 75 1.16
Left main PCI 2.04 (1.57–2.65) <0.0001 1.90 (1.62–2.23) <0.0001 75 1.16
Pre-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.76 (0.57–1.01) 0.0606 0.88 (0.71–1.09) 0.2311 1,767 27.20
Post-PCI TIMI ﬂow grade 3, reference group: TIMI ﬂow grade <3 0.31 (0.25–0.39) <0.0001 0.44 (0.37–0.51 <0.0001 1,483 22.90
Multiple logistic regressions including covariates artiﬁcial ventilation, radial procedure, and IABP use in the model. Total sample size ¼ 6,489, sample entered into MV model without missing
data¼ 2,783, total events¼ 1,118. *Odds ratio (95% CI) and p values after applying multiple imputation NMAR (all 6,489 subjects were used; total events¼ 2,872). †Case records with missing
data.
Abbreviations as in Tables 1 to 3.
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1383with primary PCI, demonstrating no beneﬁt of IABP
on outcome, which supports the ﬁndings of the ran-
domized IABP-Shock II (Intraaortic Balloon Support
for Myocardial Infarction With Cardiogenic Shock)
trial (16). A meta-analysis evaluated the effect of IABP
in the setting of AMI. IABP was associated with a
signiﬁcantly reduced risk of death in patients who
received thrombolysis (risk ratio [RR]: 0.77, p <
0.0001), and a higher risk of death in patients who
underwent PCI (RR: 1.18, p ¼ 0.01) (17). Again these
are observational data that may be confounded by the
sickest patients being selected for IABP. Although the
evidence for the use of IABP in this context is rela-
tively weak, IABP use in CGS patients undergoing PCI
in the United Kingdom remains relatively high, which
may represent physician bias and their belief that it is
useful.
In the randomized SHOCK trial, 60% of patients in
the PCI group and 80.4% of patients in the coronary
artery bypass graft group had 3-vessel coronary artery
disease (18). In the SHOCK registry, 53.4% of patients
had multivessel disease (MVD) (19). Despite the fact
that MVD appears to be a predominant ﬁnding in
patients with CGS, the best strategy of how to treat
MVD identiﬁed in the setting of CGS is unknown and
requires further evaluation. In patients with CGS,
MVD with and without a chronic occlusion were
predictors for short-term mortality (20).
We have demonstrated that history of renal disease
is an independent predictor of worse outcome at1 year. Strategies to minimize further worsening of
renal function and development of contrast-induced
nephropathy should be seriously considered in such
patients with efﬁcient angiography and PCI using as
little contrast as possible. It is unclear but intuitive
and supported by our study that multiple risk factors
for mortality in patients with CGS exist and modi-
fying each may have overall beneﬁt. Protocol-driven
intervention in the sick CGS patient, with recogni-
tion of the risk factors as demonstrated in this study
and available in catheter labs, could focus care. We
have also shown that TIMI ﬂow grade 3 post-PCI and
radial procedures were independent predictors of
survival at 1 year. Transradial access may be a marker
for patients who are less sick, because in patients
with severe end organ hypoperfusion, the radial
pulse may be impalpable and the femoral artery
would be the only possible access route. Thus the
association of lower mortality with transradial access
may be partly explained by the use of radial access in
patients who are less profoundly shocked.
STUDY LIMITATIONS. This is an observational study.
However, it is mandatory for all institutions within
the United Kingdom to submit their PCI to the
national database, and the data are sufﬁciently robust
to be used as a reference database and are publically
available as an audit of outcome. The main strength is
that our study represents all patients treated in
England and Wales in whom complete and
Kunadian et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 2 , 2 0 1 4
Cardiogenic Shock in the Contemporary Era D E C E M B E R 2 0 1 4 : 1 3 7 4 – 8 5
1384independently reported mortality data are available.
The strategies used by different operators in different
parts of the country vary and could have implications
on the outcome of patients included in our analysis. It
is possible that the deﬁnition of CGS used by opera-
tors varied between centers, and in the setting of
emergency PCI, the diagnosis is often based on clin-
ical judgment rather than objective measurements of
cardiac physiology. However, a recent analysis of the
2011 BCIS PCI audit demonstrated that the mortality
for all units for patients presenting with CGS
was within 2 SD of the funnel plot, which provides
some reassurance of consistency regarding the deﬁ-
nition of CGS across the centers within the United
Kingdom (21).
Of the data that was entered into the MV
regression model, there were missing values as
shown in Tables 3 to 6. However, signiﬁcant results
in Tables 3 to 6 would not be affected by the missing
values under the assumption that the missing data
occurred completely at random. We also conducted
further analysis based on the assumption of data not
missing at random and our main ﬁndings did not
change much as is shown in Tables 3 to 6 from the
analysis using data missing completely at random.
Furthermore, the variables entered in the MV model
were included and retained as these variables are of
clinical relevance in the management of patients with
CGS and undergoing PCI. We did not have information
regarding the following variables due to the missing
data in our registry: details of resuscitation before
procedure; details of mechanical complications;symptom onset to PCI time; door to balloon time;
details of therapeutic hypothermia; use of extracor-
poreal membrane oxygenation; and the use of left
ventricular assist device.
CONCLUSIONS
Mortality remains high in CGS. We can better predict
which patients are at higher risk of dying as a result of
this study. A novel ﬁnding is the apparent, somewhat
plateau-like nature of mortality after the early initial
attrition in survival; longer term survival is good,
allowing the focusing of attention during the acute
phase and its potential impact on longer term
mortality.
In a large U.K. cohort of patients undergoing PCI in
the context of CGS, mortality remains high in spite of
the use of contemporary PCI strategies. Further im-
provements in the early detection and management
of CGS are still required. This remains an area that
requires focused research investment.
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APPENDIX For TIMI ﬂow grade classiﬁca-
tions and the deﬁnitions of arterial complica-
tions and renal failure/dialysis used in this
study, please see the online version of this
paper.
